Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
10.1016/j.jhep.2011.11.009 122 SanyalA
1), S330 (2010)
Drug manufacturers have developed dual and triple agonists for the modulation of several metabolic pathways, which are intended to improve blood sugar levels and facilitate weight loss
Specifically, it acts as an agonist (activator) for the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor
Retatrutide (GLP3-R) is evaluated in laboratory research for: Its multi-pathway activity differentiates it from single-receptor GLP analog peptides studied in other research frameworks
Another potential plus: price
US$ 25.17
US$ 22.33
US$ 21.03
US$ 26.37
US$ 20.42
US$ 27.99
US$ 21.02
US$ 29.14
US$ 29.30
